Scoping paper on the potential risk(s) of Garcinia cambogia oral consumption

Data from authoritative bodies

TOX/2025/41

Last updated: 27 October 2025

This is a discussion paper. It does not reflect the views of the Committee. It should not be cited.

13.               Multiple authoritative bodies have reviewed the data on G. cambogia. For example, in European and international vigilance systems several reports of hepatic, digestive (pancreatitis), cardiac and muscular (rhabdomyolysis) damage as a result of consumption of supplements containing G. cambogia have been identified.